Login to Your Account



Sarcoma Phase IIb in Progress

Play Cytrx 'Albumin' Stereo: Drug Hits Glioblastoma, Too?

By Randy Osborne
Staff Writer

Wednesday, July 10, 2013
Cytrx Corp.'s decision to stop in May its Phase IIb trial with the synthetic retinoid tamibarotene for non-small-cell lung cancer turned investor eyes to aldoxorubicin, an improved, albumin-binding form of the chemotherapy drug doxorubicin at the same stage of testing in first-line soft-tissue sarcoma (STS).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription